Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x100px
Organisation › Details

Step Pharma SAS

Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of oncology and autoimmune diseases. The company has identified several inhibitors of CTPS1, with the most advanced, STP938 being prepared for clinical studies in T-cell malignancies. Step Pharma was founded in June 2014 by Kurma Partners, the Imagine Institute, and Sygnature Discovery based on the scientific discoveries of Prof. Alain Fischer and Dr Sylvain Latour’s laboratory at the Imagine Institute, Paris. Step Pharma is based in Archamps, France. *


Period Start 2014-06-01 established
Products Industry CTPS1 inhibitor
  Industry 2 drug development
Person Person Parker, Andrew (Step Pharma 201909– CEO before Zealand Pharma + Eclosion2 + AstraZeneca + JnJ + Opsana Therapeutics)
Region Region Archamps
  Country France
  Street 218 avenue Marie Curie
Forum 2
  City 74160 Archamps
  Tel +33-7-8154-8061
    Address record changed: 2021-03-25
Basic data Employees n. a.
    * Document for »About Section«: Step Pharma SAS. (3/24/21). "Press Release: Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1 inhibitor into the Clinic in T Cell Malignancies". Archamps.
Record changed: 2024-03-30


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Step Pharma SAS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px

» top